Switch to:
Also traded in: Denmark, Germany, Switzerland, UK, USA
» Details

Insider Trades

Latest Guru Trades with OTCPK:NONOF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2836
Compare:NAS:GILD, NAS:CELG, NAS:BIIB, OTCPK:SHPGF, NAS:AMGN, OTCPK:CSLLY, NAS:REGN, NAS:ALXN, OTCPK:ALIOY, NAS:INCY, NAS:VRTX, OTCPK:GIKLY, NAS:BMRN, OTCPK:UCBJY, OTCPK:GMXAY, OTCPK:NVZMF, NAS:SGEN, NAS:JAZZ, NAS:ALKS, NAS:UTHR » details
Traded in other countries:NOVO B.Denmark, NOVA.Germany, NOVOB.Switzerland, 0QIU.UK, NVO.USA,
Novo-Nordisk A/S is a healthcare company that is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company has two business segments: diabetes care and biopharmaceuticals.

Novo Nordisk A/S is a healthcare company incorporated on November 28, 1931 in Denmark. The Company has diabetes product portfolios, including new generation insulins, a full portfolio of modern insulins as well as a human once-daily GLP-1 analog. In addition, it also has a position within haemophilia care, growth hormone therapy and hormone replacement therapy, and Company's first product to treat obesity, Saxenda, was launched in the United States in April 2015 and is also available in Denmark, Italy and Canada. The Company manufactures and markets pharmaceutical products and services that make a difference to patients, the medical profession and society. The Company is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products and has two business segments: diabetes & obesity care and biopharmaceuticals. The diabetes care segment covers insulins, GLP-1, other protein-related products (such as glucagon, protein-related delivery systems and needles), oral anti-diabetic drugs and obesity. The biopharmaceuticals segment covers the therapy areas of haemophilia care, growth hormone therapy and hormone replacement therapy. The Company's insulin and other pharmaceutical products are marketed and distributed through subsidiaries, distributors and independent agents with responsibility for specific geographical areas. The important markets are North America, China, Japan and the European countries. In addition there is an increasing contribution to its total sales from key markets in the sales region International Operations such as Saudi Arabia, Algeria, Turkey, Argentina, Australia, India, Brazil, Iran and Russia.

Ratios

vs
industry
vs
history
PE Ratio 16.66
NONOF's PE Ratio is ranked higher than
70% of the 188 Companies
in the Global Biotechnology industry.

( Industry Median: 26.13 vs. NONOF: 16.66 )
Ranked among companies with meaningful PE Ratio only.
NONOF' s PE Ratio Range Over the Past 10 Years
Min: 12.13  Med: 23.57 Max: 34.41
Current: 16.66
12.13
34.41
Forward PE Ratio 16.23
NONOF's Forward PE Ratio is ranked higher than
64% of the 76 Companies
in the Global Biotechnology industry.

( Industry Median: 20.00 vs. NONOF: 16.23 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 16.66
NONOF's PE Ratio without NRI is ranked higher than
71% of the 185 Companies
in the Global Biotechnology industry.

( Industry Median: 26.61 vs. NONOF: 16.66 )
Ranked among companies with meaningful PE Ratio without NRI only.
NONOF' s PE Ratio without NRI Range Over the Past 10 Years
Min: 12.13  Med: 23.55 Max: 34.41
Current: 16.66
12.13
34.41
Price-to-Owner-Earnings 18.99
NONOF's Price-to-Owner-Earnings is ranked higher than
60% of the 128 Companies
in the Global Biotechnology industry.

( Industry Median: 25.00 vs. NONOF: 18.99 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
NONOF' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 13.81  Med: 27.91 Max: 59.57
Current: 18.99
13.81
59.57
PB Ratio 14.04
NONOF's PB Ratio is ranked lower than
89% of the 556 Companies
in the Global Biotechnology industry.

( Industry Median: 3.85 vs. NONOF: 14.04 )
Ranked among companies with meaningful PB Ratio only.
NONOF' s PB Ratio Range Over the Past 10 Years
Min: 3.68  Med: 8.82 Max: 31.9
Current: 14.04
3.68
31.9
PS Ratio 5.65
NONOF's PS Ratio is ranked higher than
62% of the 477 Companies
in the Global Biotechnology industry.

( Industry Median: 9.96 vs. NONOF: 5.65 )
Ranked among companies with meaningful PS Ratio only.
NONOF' s PS Ratio Range Over the Past 10 Years
Min: 2.8  Med: 5.8 Max: 11.01
Current: 5.65
2.8
11.01
Price-to-Free-Cash-Flow 15.78
NONOF's Price-to-Free-Cash-Flow is ranked higher than
66% of the 114 Companies
in the Global Biotechnology industry.

( Industry Median: 23.86 vs. NONOF: 15.78 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
NONOF' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 12.07  Med: 24.45 Max: 47.08
Current: 15.78
12.07
47.08
Price-to-Operating-Cash-Flow 13.07
NONOF's Price-to-Operating-Cash-Flow is ranked higher than
69% of the 158 Companies
in the Global Biotechnology industry.

( Industry Median: 22.05 vs. NONOF: 13.07 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
NONOF' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 9.91  Med: 19.82 Max: 32.54
Current: 13.07
9.91
32.54
EV-to-EBIT 12.67
NONOF's EV-to-EBIT is ranked higher than
63% of the 196 Companies
in the Global Biotechnology industry.

( Industry Median: 18.89 vs. NONOF: 12.67 )
Ranked among companies with meaningful EV-to-EBIT only.
NONOF' s EV-to-EBIT Range Over the Past 10 Years
Min: 9.2  Med: 16.7 Max: 25.7
Current: 12.67
9.2
25.7
EV-to-EBITDA 11.89
NONOF's EV-to-EBITDA is ranked higher than
60% of the 213 Companies
in the Global Biotechnology industry.

( Industry Median: 16.23 vs. NONOF: 11.89 )
Ranked among companies with meaningful EV-to-EBITDA only.
NONOF' s EV-to-EBITDA Range Over the Past 10 Years
Min: 8.2  Med: 16.1 Max: 23.6
Current: 11.89
8.2
23.6
PEG Ratio 0.97
NONOF's PEG Ratio is ranked higher than
70% of the 89 Companies
in the Global Biotechnology industry.

( Industry Median: 1.81 vs. NONOF: 0.97 )
Ranked among companies with meaningful PEG Ratio only.
NONOF' s PEG Ratio Range Over the Past 10 Years
Min: 0.66  Med: 1.48 Max: 5.14
Current: 0.97
0.66
5.14
Shiller PE Ratio 31.15
NONOF's Shiller PE Ratio is ranked higher than
69% of the 55 Companies
in the Global Biotechnology industry.

( Industry Median: 47.81 vs. NONOF: 31.15 )
Ranked among companies with meaningful Shiller PE Ratio only.
NONOF' s Shiller PE Ratio Range Over the Past 10 Years
Min: 23.23  Med: 44.07 Max: 67.69
Current: 31.15
23.23
67.69
Current Ratio 1.26
NONOF's Current Ratio is ranked lower than
81% of the 585 Companies
in the Global Biotechnology industry.

( Industry Median: 3.45 vs. NONOF: 1.26 )
Ranked among companies with meaningful Current Ratio only.
NONOF' s Current Ratio Range Over the Past 10 Years
Min: 1.26  Med: 2.14 Max: 2.45
Current: 1.26
1.26
2.45
Quick Ratio 0.96
NONOF's Quick Ratio is ranked lower than
83% of the 583 Companies
in the Global Biotechnology industry.

( Industry Median: 3.24 vs. NONOF: 0.96 )
Ranked among companies with meaningful Quick Ratio only.
NONOF' s Quick Ratio Range Over the Past 10 Years
Min: 0.96  Med: 1.45 Max: 1.91
Current: 0.96
0.96
1.91
Days Inventory 288.81
NONOF's Days Inventory is ranked lower than
84% of the 314 Companies
in the Global Biotechnology industry.

( Industry Median: 129.42 vs. NONOF: 288.81 )
Ranked among companies with meaningful Days Inventory only.
NONOF' s Days Inventory Range Over the Past 10 Years
Min: 246.45  Med: 282.52 Max: 343.56
Current: 288.81
246.45
343.56
Days Sales Outstanding 66.07
NONOF's Days Sales Outstanding is ranked lower than
54% of the 405 Companies
in the Global Biotechnology industry.

( Industry Median: 62.87 vs. NONOF: 66.07 )
Ranked among companies with meaningful Days Sales Outstanding only.
NONOF' s Days Sales Outstanding Range Over the Past 10 Years
Min: 45.09  Med: 51.9 Max: 66.07
Current: 66.07
45.09
66.07
Days Payable 127.69
NONOF's Days Payable is ranked higher than
75% of the 277 Companies
in the Global Biotechnology industry.

( Industry Median: 56.51 vs. NONOF: 127.69 )
Ranked among companies with meaningful Days Payable only.
NONOF' s Days Payable Range Over the Past 10 Years
Min: 72.54  Med: 100.02 Max: 127.69
Current: 127.69
72.54
127.69

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 3.96
NONOF's Dividend Yield % is ranked higher than
90% of the 235 Companies
in the Global Biotechnology industry.

( Industry Median: 1.45 vs. NONOF: 3.96 )
Ranked among companies with meaningful Dividend Yield % only.
NONOF' s Dividend Yield % Range Over the Past 10 Years
Min: 0.93  Med: 1.56 Max: 4.17
Current: 3.96
0.93
4.17
Dividend Payout Ratio 0.64
NONOF's Dividend Payout Ratio is ranked lower than
81% of the 126 Companies
in the Global Biotechnology industry.

( Industry Median: 0.35 vs. NONOF: 0.64 )
Ranked among companies with meaningful Dividend Payout Ratio only.
NONOF' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.26  Med: 0.35 Max: 0.64
Current: 0.64
0.26
0.64
3-Year Dividend Growth Rate 37.70
NONOF's 3-Year Dividend Growth Rate is ranked higher than
89% of the 82 Companies
in the Global Biotechnology industry.

( Industry Median: 7.00 vs. NONOF: 37.70 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
NONOF' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 12.7  Med: 28.9 Max: 37.7
Current: 37.7
12.7
37.7
Forward Dividend Yield % 3.13
NONOF's Forward Dividend Yield % is ranked higher than
83% of the 226 Companies
in the Global Biotechnology industry.

( Industry Median: 1.34 vs. NONOF: 3.13 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 15.81
NONOF's 5-Year Yield-on-Cost % is ranked higher than
56% of the 291 Companies
in the Global Biotechnology industry.

( Industry Median: 1.59 vs. NONOF: 15.81 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
NONOF' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 3.71  Med: 6.23 Max: 16.65
Current: 15.81
3.71
16.65
3-Year Average Share Buyback Ratio 1.80
NONOF's 3-Year Average Share Buyback Ratio is ranked higher than
97% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: -10.60 vs. NONOF: 1.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
NONOF' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -3.1  Med: 1.5 Max: 8
Current: 1.8
-3.1
8

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 85.07
NONOF's Price-to-Net-Current-Asset-Value is ranked lower than
96% of the 387 Companies
in the Global Biotechnology industry.

( Industry Median: 6.60 vs. NONOF: 85.07 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
NONOF' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 11.62  Med: 24.24 Max: 100.73
Current: 85.07
11.62
100.73
Price-to-Tangible-Book 14.95
NONOF's Price-to-Tangible-Book is ranked lower than
85% of the 494 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. NONOF: 14.95 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
NONOF' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 3.14  Med: 6.39 Max: 23.2
Current: 14.95
3.14
23.2
Price-to-Intrinsic-Value-Projected-FCF 1.47
NONOF's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
78% of the 156 Companies
in the Global Biotechnology industry.

( Industry Median: 3.03 vs. NONOF: 1.47 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
NONOF' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.45  Med: 2.5 Max: 7.38
Current: 1.47
1.45
7.38
Price-to-Intrinsic-Value-DCF (Earnings Based) 0.59
NONOF's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked higher than
90% of the 20 Companies
in the Global Biotechnology industry.

( Industry Median: 0.99 vs. NONOF: 0.59 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
N/A
Price-to-Median-PS-Value 0.98
NONOF's Price-to-Median-PS-Value is ranked higher than
51% of the 425 Companies
in the Global Biotechnology industry.

( Industry Median: 0.99 vs. NONOF: 0.98 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
NONOF' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.5  Med: 0.86 Max: 1.65
Current: 0.98
0.5
1.65
Price-to-Peter-Lynch-Fair-Value 0.84
NONOF's Price-to-Peter-Lynch-Fair-Value is ranked higher than
74% of the 66 Companies
in the Global Biotechnology industry.

( Industry Median: 1.55 vs. NONOF: 0.84 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
NONOF' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.27  Med: 1.02 Max: 3.78
Current: 0.84
0.27
3.78
Price-to-Graham-Number 3.33
NONOF's Price-to-Graham-Number is ranked lower than
66% of the 144 Companies
in the Global Biotechnology industry.

( Industry Median: 2.51 vs. NONOF: 3.33 )
Ranked among companies with meaningful Price-to-Graham-Number only.
NONOF' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.56  Med: 2.8 Max: 5.52
Current: 3.33
1.56
5.52
Earnings Yield (Greenblatt) % 7.90
NONOF's Earnings Yield (Greenblatt) % is ranked higher than
89% of the 639 Companies
in the Global Biotechnology industry.

( Industry Median: -6.50 vs. NONOF: 7.90 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
NONOF' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 3.9  Med: 6 Max: 10.8
Current: 7.9
3.9
10.8
Forward Rate of Return (Yacktman) % 23.90
NONOF's Forward Rate of Return (Yacktman) % is ranked higher than
64% of the 119 Companies
in the Global Biotechnology industry.

( Industry Median: 15.08 vs. NONOF: 23.90 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
NONOF' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 7.5  Med: 16.7 Max: 33.7
Current: 23.9
7.5
33.7

More Statistics

Revenue (TTM) (Mil) $16,551
EPS (TTM) $ 2.22
Beta0.90
Short Percentage of Float0.00%
52-Week Range $31.07 - 58.05
Shares Outstanding (Mil)2,550.00

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 16,476 17,680 18,051
EPS ($) 2.23 2.39 2.54
EPS without NRI ($) 2.23 2.39 2.54
EPS Growth Rate
(Future 3Y To 5Y Estimate)
6.75%
Dividends per Share ($) 1.23 1.56 1.67
» More Articles for OTCPK:NONOF

Headlines

Articles On GuruFocus.com
While Big Diabetes Stagnates, Smaller Companies Are Moving Faster Than Ever Feb 09 2017 
Beaten-Down Valuation and a 3% Dividend Yield Feb 07 2017 
Value Screeners Identify Top Sectors Feb 06 2017 
7 Stocks for 2017 Jan 20 2017 
Something Strange Is Going On With Oral Insulin Dec 23 2016 
Gurus Invest in Undervalued Biotech Stocks Nov 25 2016 
23 Questions With Thomas Macpherson of Nintai Partners Nov 21 2016 
Graham's 4 Vital Elements Nov 10 2016 
World Leader in Diabetes Medication Hits 2-Year Low Nov 07 2016 
Buy Health Care Now? It All Depends on the Election Nov 07 2016 

More From Other Websites
Novo Nordisk North American head quits for top job at Falck Mar 01 2017
Novo Nordisk replaces head of North American operations Mar 01 2017
9 Top Pharmaceutical Stocks to Buy for the Dividends Feb 15 2017
Denmark joins race to host EU drug agency instead of London after Brexit Feb 08 2017
Novo Nordisk A/S :NONOF-US: Earnings Analysis: 2016 By the Numbers : February 7, 2017 Feb 07 2017
Beaten-Down Valuation and a 3% Dividend Yield Feb 07 2017
Novo Nordisk (NVO) Misses Q4 Earnings, Revenues Down Y/Y Feb 03 2017
European shares fall weighed down by poor earnings; Reckitt up Feb 02 2017
European shares fall weighed down by poor earnings; Reckitt up Feb 02 2017
European shares fall weighed down by poor earnings; Reckitt up Feb 02 2017
Novo Nordisk misses 4Q profit forecasts Feb 02 2017
Novo Nordisk misses 4Q profit forecasts Feb 02 2017
Falling US prices hurt Danish Novo Nordisk profit Feb 02 2017
Novo Nordisk Slumps on Disappointing Profit, Guidance Cut Feb 02 2017
European shares edge lower on disappointing company updates Feb 02 2017
European shares edge lower on disappointing company updates Feb 02 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK